Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers

Journal of Thoracic Oncology

Volumn 4, Issue 11, 2009, Pages 1352-1356

  Pastorino, Ugo ^a   Landoni, Claudio ^b   Marchianò, Alfonso ^a   Calabrò, Elisa ^a   Sozzi, Gabriella ^a   Miceli, Rosalba ^a   Picchio, Maria ^b   Mariani, Luigi ^a   Messa, Cristina ^b   Fazio, Ferruccio ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b INSTITUTE OF MOLECULAR BIOIMAGING AND PHYSIOLOGY   (Italy)

Author keywords

FDG PET; Lung cancer screening; Standardized uptake value

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RISK REDUCTION; SMOKING HABIT; SURVIVAL RATE;

EID: 70449613891     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181bbf1dc     Document Type: Article

References (29)

1. Peto R, Lopez AD, Boreham J, et al. Mortality from smoking worldwide. Br Med Bull 1996;52:12-21.
2. SEER*Stat Release 6.3.5. Available at: http://seer.cancer.gov/ seerstat/. Accessed May 28, 2007.
3. Verdecchia A, Francisci S, Brenner H, et al. EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-2002 period analysis of EUROCARE 4 data. Lancet Oncol 2007;8:784-796.
4. Henschke CI, Yankelevitz DF, Libby DM, et al. Does screening for stage I lung cancer improve survival in a high-risk population? Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-1771.
5. Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening and lung cancer outcomes. JAMA 2007;297:953-961. (Pubitemid 46376749)
6. Marcus PM, Bergstral EJ, Zweig MH, et al. Extended Lung Cancer Incidence Follow-up in the Mayo Lung Project and Overdiagnosis. J Natl Cancer Inst 2006;98:748-756.
7. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-924.
8. Vansteenkiste J, Fischer BM, Dooms C, et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004;5:531-540.
9. Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593-597.
10. Hellwig D, Ukena D, Paulsen F, et al. Onko-PET der Deutschen Gesellschaft fur Nuklearmedizin. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie 2001;55:367-377.
11. Hickeson M, Yun M, Matthies A, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002;29:1639-1647.
12. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-924.
13. Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007; 48: 214-220.
14. Kutlu CA, Pastorino U, Maisey M, et al. Selective use of PET scan in the preoperative staging of NSCLC. Lung Cancer 1998;21:177-184.
15. Pastorino U, Veronesi G, Landoni M, et al. FDG-PET improves preoperative staging of resectable lung metastasis. J Thorac Cardiovasc Surg 2003;126:1906-1910.
16. Vansteenkiste JF. PET scan in the staging of non-small cell lung cancer. Lung Cancer 2003;42:S27-S37.
17. Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol 2003; 45:49-59. (Pubitemid 36020310)
18. Cherana SK, Herndon JE II, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317-325.
19. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-1392.
20. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience 1. Radiology 2005;235:259-265.
21. Heyneman LE, Patz EF Jr. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002;38:261-266.
22. Nomori H, Watanabe K, Ohtsuka M, et al. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 2004;45:19-27.
23. Port JL, Andrade RS, Levin MA, et al. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg 2005;130:1611-1615.
24. Lindell RM, Hartman TE, Swensen SJ, et al. Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest ct in a high-risk population. Amercan Journal of Radiology. 2005;185:126-131.
25. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
26. Fee de Geus-Oei L, van der Heijden HFM, Corstens FHM, et al. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer. A systematic review. Cancer 2007;110:1654-1664.
27. Berghmans T, Dusart M, Marianne Paesmans M, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC). A systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008; 3:6-12.
28. Vesselle H, Grierson J, Muzi M, et al. In Vivo Validation of 3′deoxy- 3′-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-3323.
29. Vazquez M, Carter D, Brambilla E, et al. The International Early Lung Cancer Action Program Investigators. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer 2009;64:148-154.